Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Palmitoyltransferase ZDHHC22 is a member of the DHHC family of protein palmitoyltransferases, characterized by the presence of a zinc finger DHHC domain. It catalyzes the S-palmitoylation of target proteins, such as KCNMA1, influencing their localization and function at the plasma membrane. ZDHHC22 has enzymatic activity dependent on its DHHC motif and can regulate key signaling pathways by palmitoylating substrates like mTOR, thereby affecting the AKT/mTOR pathway. In breast cancer, ZDHHC22 acts as a tumor suppressor by limiting cell proliferation and promoting apoptosis through cell cycle arrest; its downregulation is associated with increased cancer cell growth and tamoxifen resistance. ZDHHC22 is considered an enzyme target with a potential therapeutic role in oncology, though no direct drug modulators or inhibitors are currently available or reported in clinical or preclinical studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Palmitoyltransferase ZDHHC22 (ZDHHC22).